VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) and Compugen (NASDAQ:CGEN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
Profitability
This table compares VistaGen Therapeutics and Compugen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
| Compugen | 47.56% | 42.57% | 26.13% |
Analyst Recommendations
This is a summary of recent ratings and target prices for VistaGen Therapeutics and Compugen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
| Compugen | 0 | 1 | 3 | 1 | 3.00 |
Risk and Volatility
VistaGen Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500.
Insider and Institutional Ownership
78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares VistaGen Therapeutics and Compugen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VistaGen Therapeutics | $1.27 million | 12.87 | -$69.68 million | ($1.66) | -0.22 |
| Compugen | $72.76 million | 3.04 | $35.34 million | $0.38 | 6.16 |
Compugen has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Summary
Compugen beats VistaGen Therapeutics on 12 of the 15 factors compared between the two stocks.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
